# Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct07006077/  
OnCo record `nct07006077` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Recombinant human IL-21-expressing oncolytic vaccinia virus injection in pancreatic ductal adenocarcinoma, run by Hangzhou Converd Co., Ltd., now recruiting.

## Summary

Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer is a phase 2 interventional study registered as NCT07006077 by Hangzhou Converd Co., Ltd., with 12 participants planned, started 2025-05-29 and due to reach its primary completion in 2028-12-31. Interventions recorded: Recombinant human IL-21-expressing oncolytic vaccinia virus injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07006077
- Phase: 2
- Setting: A Phase II Trial to Evaluate the Efficacy of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Patients With Advanced Pancreatic Tumors
- Sponsor: Hangzhou Converd Co., Ltd.
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT07006077: https://clinicaltrials.gov/study/NCT07006077

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/nct07006077.json